Display options
Cite
Ghorbani-Aghbolaghi A, Darrow MA, Wang T. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss. Autops Case Rep. 2017;7(3):32-37doi: 10.4322/acr.2017.031.
Ghorbani-Aghbolaghi, A., Darrow, M. A., & Wang, T. (2017). Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss. Autopsy & case reports, 7(3), 32-37. https://doi.org/10.4322/acr.2017.031
Ghorbani-Aghbolaghi, Amir, et al. "Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss." Autopsy & case reports vol. 7,3 (2017): 32-37. doi: https://doi.org/10.4322/acr.2017.031
Ghorbani-Aghbolaghi A, Darrow MA, Wang T. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss. Autops Case Rep. 2017 Sep 30;7(3):32-37. doi: 10.4322/acr.2017.031. eCollection 2017. PMID: 29043208; PMCID: PMC5634432.
Copy Download .nbib Format: NLM
Share it on

Autops Case Rep. 2017 Sep 30;7(3):32-37. doi: 10.4322/acr.2017.031. eCollection 2017.

Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.

Autopsy & case reports

Amir Ghorbani-Aghbolaghi, Morgan Angus Darrow, Tao Wang

Affiliations

  1. University of California, Davis, Department of Pathology, Laboratory Medicine. Sacramento, CA, USA.

PMID: 29043208 PMCID: PMC5634432 DOI: 10.4322/acr.2017.031

Abstract

Phosphaturic mesenchymal tumors (PMTs) are very rare tumors which are frequently associated with Tumor Induced Osteomalacia (TIO), a paraneoplastic syndrome that manifests as renal phosphate wasting. The tumor cells produce a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23), a physiologic regulator of phosphate levels. FGF23 decreases proximal tubule reabsorption of phosphates and inhibits 1-α-hydroxylase, which reduces levels of 1-α, 25-dihydroxyvitamine D3. Thus, overexpression of FGF23 by the tumor cells leads to increased excretion of phosphate in the urine, mobilization of calcium and phosphate from bones, and the reduction of osteoblastic activity, ultimately resulting in widespread osteomalacia. Patients typically present with gradual muscular weakness and diffuse bone pain from pathologic fractures. The diagnosis is often delayed due to the non-specific nature of the symptoms and lack of clinical suspicion. While serum phosphorus and FGF23 testing can assist in making a clinical diagnosis of PMT, the responsible tumor is often difficult to locate. The pathologic diagnosis is often missed due to the rarity of PMTs and histologic overlap with other mesenchymal neoplasms. While patients can experience severe disabilities without treatment, excision is typically curative and results in a dramatic reversal of symptoms. Histologically, PMT has a variable appearance and can resemble other low grade mesenchymal tumors. Even though very few cases of PMT have been reported in the world literature, it is very important to consider this diagnosis in all patients with hypophosphatemic osteomalacia. Here we present a patient who suffered for almost 5 years without a diagnosis. Ultimately, the PMT was located on a 68Ga-DOTA TATE PET/CT scan and subsequently confirmed by histologic and immunohistologic study. Interestingly, strong positivity for FGFR1 by IHC might be related to the recently described FN1-FGFR1 fusion. Upon surgical removal, the patient's phosphate and FGF23 levels returned to normal and the patient's symptoms resolved.

Keywords: Bone Diseases, Metabolic; Fibroblast Growth factors; Hypophosphatemia; Neoplasm, Connective Tissue; Oncogenic Osteomalacia

Conflict of interest statement

Conflict of interest: None

References

  1. J Pathol. 2016 Mar;238(4):502-7 - PubMed
  2. Nat Genet. 2000 Nov;26(3):345-8 - PubMed
  3. J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3 - PubMed
  4. Am J Med. 2005 Oct;118(10):1094-101 - PubMed
  5. Nat Rev Endocrinol. 2012 Jan 17;8(5):276-86 - PubMed
  6. Skeletal Radiol. 2000 Mar;29(3):117-24 - PubMed
  7. Kidney Int Suppl. 2011 Apr;(121):S24-7 - PubMed
  8. Int J Clin Exp Pathol. 2015 Aug 01;8(8):9422-7 - PubMed
  9. Ageing Res Rev. 2002 Sep;1(4):627-38 - PubMed
  10. Clin Exp Otorhinolaryngol. 2012 Sep;5(3):173-6 - PubMed
  11. Am J Surg Pathol. 2004 Jan;28(1):1-30 - PubMed
  12. Curr Opin Nephrol Hypertens. 2002 Jul;11(4):385-9 - PubMed
  13. J Dermatol. 2014 Sep;41(9):845-9 - PubMed
  14. Mod Pathol. 2016 Nov;29(11):1335-1346 - PubMed
  15. Am J Physiol Renal Physiol. 2007 Nov;293(5):F1577-83 - PubMed
  16. J Biol Chem. 1996 Jun 21;271(25):15292-7 - PubMed
  17. Nat Rev Drug Discov. 2009 Mar;8(3):235-53 - PubMed
  18. Cancer Res. 2006 Jan 1;66(1):315-23 - PubMed
  19. PLoS One. 2013;8(2):e57322 - PubMed
  20. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6500-5 - PubMed
  21. J Pathol. 2015 Mar;235(4):539-45 - PubMed

Publication Types